DNAprint Genomics (DNAG)

[johnnyfiber]

ITS ALL RIGHT THERE

BC-LOH
BC-LOH is a genetic test we are developing for mapping the relapse risk-status of normal tissue surrounding a breast tumor. The technology could help oncologists determine whether a mastectomy is warranted, and could help save many breast cancer patients from unnecessary mastectomy.



--------------------------------------------------------------------------------

BACK TO TOP

Ondansetron
Through collaboration with the Moffitt Cancer Research Center in Tampa, FL, we are investigating the genetic basis of Ondansetron response. Ondansetron is an anti-emetic for the alleviation of post-operative nausea and vomiting (PONV), but normal doses of the drug do not elicit the desired effect in some patients. A genetic test for predicting Ondansetron response could help reduce extreme discomfort many patients feel after surgery.

March 29, 2004 DNAPrint™ genomics, Inc. Forms Joint Research Program with the H. Lee Moffitt Cancer Center and Research Institute



--------------------------------------------------------------------------------

BACK TO TOP

Melphalan/Topotecan
Through collaboration with the Moffitt Cancer Research Center in Tampa, FL, we are investigating the genetic basis of Melphalan/Topotecan (MT) response in multiple myeloma patients. MT is a chemotherapy that prevents the cell division that tumors need to grow but for some patients, normal doses do not elicit the desired effect. A genetic test for predicting MT response could help minimize the likelihood of multiple myeloma relapse.

March 29, 2004 DNAPrint™ genomics, Inc. Forms Joint Research Program with the H. Lee Moffitt Cancer Center and Research Institute



--------------------------------------------------------------------------------

BACK TO TOP

Xeleri/Xelox
Through collaboration with the Moffitt Cancer Research Center in Tampa, FL, we are investigating the genetic basis of Xeleri/Xelox response for colon cancer patients. Xeleri/Xelox is a chemotherapy that prevents the cell division that tumors need to grow but for some patients, normal doses do not elicit the desired effect. A genetic test for predicting Xeleri/Xelox response could help minimize the likelihood of colon cancer relapse.

March 29, 2004 DNAPrint™ genomics, Inc. Forms Joint Research Program with the H. Lee Moffitt Cancer Center and Research Institute